In summary, we demonstrate that miR‐495‐3p diminishes Dox‐induced cardiotoxicity through activating AKT pathway, and targeting miR‐495‐3p may provide novel cardioprotective approaches for cancer patients receiving anthracycline chemotherapy. Here, AKT1 is linked to cancer.